US Most Favored Nation Policy Threatens Access to New Drugs in Sweden

The recent implementation of the United States' Most Favored Nation (MFN) policy on drug pricing is causing significant delays and reductions in the launch of new pharmaceutical treatments in Sweden, raising concerns about patient access and the country's pharmaceutical landscape. According to a survey conducted by Lif, the organization representing research-based pharmaceutical companies in Sweden, more than half of the 35 surveyed companies anticipate refraining from launching certain new drugs in the Swedish market within the next three years. Additionally, two-thirds expect to scale back clinical trials conducted in Sweden.

Data from GlobalData reveals a 56% decline in drug launches in Sweden since the MFN policy was introduced in May 2025, a trend reflecting broader setbacks across Europe. This decline is attributed to the policy’s mechanism linking US drug prices to the lowest prices offered in several European countries, creating uncertainties for pharmaceutical companies heavily reliant on the US market for sales.

Lif's CEO, Sofia Wallström, highlighted the serious consequences this policy may have on Sweden’s pharmaceutical ecosystem and patient care. She warned that extended delays or cancellations in the introduction of new medicines could lead to reduced access to vital treatments for Swedish patients. Wallström urged the Swedish government to promptly address these challenges by establishing a dedicated task force to recommend solutions that ensure patients continue to have access to innovative therapies and to uphold Sweden's reputation as a leading nation in life sciences.

In response, the Swedish government has initiated a comprehensive analysis of the MFN policy’s impact on the country's pharmaceutical sector and is conducting a broader review of the national drug system to mitigate potential adverse effects. These measures demonstrate the government's recognition of the issue’s urgency and its commitment to maintaining Sweden’s access to new drugs amid shifting international policies.